MDT

95.31

-1.26%↓

VEEV

287.1

-0.28%↓

A

139.44

+0.99%↑

HQY

92.23

-1.52%↓

TLRY

1.67

+5.03%↑

MDT

95.31

-1.26%↓

VEEV

287.1

-0.28%↓

A

139.44

+0.99%↑

HQY

92.23

-1.52%↓

TLRY

1.67

+5.03%↑

MDT

95.31

-1.26%↓

VEEV

287.1

-0.28%↓

A

139.44

+0.99%↑

HQY

92.23

-1.52%↓

TLRY

1.67

+5.03%↑

MDT

95.31

-1.26%↓

VEEV

287.1

-0.28%↓

A

139.44

+0.99%↑

HQY

92.23

-1.52%↓

TLRY

1.67

+5.03%↑

MDT

95.31

-1.26%↓

VEEV

287.1

-0.28%↓

A

139.44

+0.99%↑

HQY

92.23

-1.52%↓

TLRY

1.67

+5.03%↑

Search

Kura Oncology Inc

Fechado

SetorSaúde

10.29 6.52

Visão Geral

Variação de preço das ações

24h

Atual

Mín

9.62

Máximo

10.33

Indicadores-chave

By Trading Economics

Rendimento

-8.7M

-66M

Vendas

1.2M

15M

Margem de lucro

-432.509

Funcionários

192

EBITDA

-8M

-73M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+170.27% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de nov. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

315M

862M

Abertura anterior

3.77

Fecho anterior

10.29

Sentimento de Notícias

By Acuity

60%

40%

323 / 371 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Kura Oncology Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

15 de out. de 2025, 23:25 UTC

Grandes Movimentos do Mercado

Salesforce Rises on New FY30 Financial Targets

15 de out. de 2025, 18:52 UTC

Ganhos
Grandes Movimentos do Mercado

Prologis Shares Gain on Raised Outlook, Data Center Growth

15 de out. de 2025, 18:30 UTC

Aquisições, Fusões, Aquisições de Empresas

Constellation Software to Buy U.K.'s Tecvia Holding

15 de out. de 2025, 17:19 UTC

Aquisições, Fusões, Aquisições de Empresas

Drahi's Altice Rejects $20 Billion Joint Offer From Peers -- 2nd Update

15 de out. de 2025, 17:11 UTC

Aquisições, Fusões, Aquisições de Empresas

Anglo American, MMG Offer Concessions to EU Merger Watchdog in Nickel Deal Probe

15 de out. de 2025, 23:48 UTC

Conversa de Mercado

Gold Steady, Supported by Expectations of Ongoing Central Bank Purchases -- Market Talk

15 de out. de 2025, 23:38 UTC

Conversa de Mercado

Nikkei May Rise, Tracking Gains Across Most U.S. Equity Markets -- Market Talk

15 de out. de 2025, 22:37 UTC

Conversa de Mercado

Economic Stars Are Aligning for RBA -- Market Talk

15 de out. de 2025, 21:44 UTC

Ganhos

Stock Rally Is Lifting Wealth Managers. How Much Is Charles Schwab Benefiting? -- Barrons.com

15 de out. de 2025, 20:50 UTC

Conversa de Mercado
Ganhos

Financial Services Roundup: Market Talk

15 de out. de 2025, 20:44 UTC

Aquisições, Fusões, Aquisições de Empresas

Restaurant Brands Recommends Hldrs Do Not Tender Their Shrs to the Offer >QSR.T

15 de out. de 2025, 20:44 UTC

Aquisições, Fusões, Aquisições de Empresas

Restaurant Brands Notified of Unsolicited Mini-Tender Offer to Buy Shrs at $28.80/Shr

15 de out. de 2025, 20:43 UTC

Aquisições, Fusões, Aquisições de Empresas

Restaurant Brands Notified of Unsolicited Mini-Tender Offer by NY Stk and Bond LLC to Purchase Up to 10,000 Common Shrs >QSR.T

15 de out. de 2025, 20:34 UTC

Ganhos

Prologis Raises Outlook as Warehouse Leasing Picks Up -- WSJ

15 de out. de 2025, 20:31 UTC

Aquisições, Fusões, Aquisições de Empresas

RBI Recommends Hldrs Reject NYSB's "Mini-Tender Offer"

15 de out. de 2025, 20:17 UTC

Aquisições, Fusões, Aquisições de Empresas

GE Vernova Stock Feill With Latest Call to Sell -- Barrons.com

15 de out. de 2025, 19:06 UTC

Ganhos

These Stocks Are Moving the Most Today: Bank of America, Morgan Stanley, ASML, AMD, Nvidia, Bunge, Progressive, Abbott, and More -- Barrons.com

15 de out. de 2025, 19:04 UTC

Conversa de Mercado

Oil Futures Post Back-to-Back Losses -- Market Talk

15 de out. de 2025, 18:46 UTC

Conversa de Mercado

U.S. Natural Gas Futures Slip Ahead of Storage Data -- Market Talk

15 de out. de 2025, 18:23 UTC

Ganhos

This Insurer Is the One of the Worst Stocks in the S&P 500 Today. Here's Why. -- Barrons.com

15 de out. de 2025, 17:37 UTC

Aquisições, Fusões, Aquisições de Empresas

Constellation Software's Harris Operating Group Enters Into Agreement To Acquire TECVIA Holding GmbH >CSU.T

15 de out. de 2025, 17:34 UTC

Conversa de Mercado

Oil Futures Lose Ground on Trade, Oversupply Concerns -- Market Talk

15 de out. de 2025, 16:57 UTC

Ganhos

The Nation's Biggest Banks Are Saying the Economy Is Still Strong -- WSJ

15 de out. de 2025, 16:51 UTC

Aquisições, Fusões, Aquisições de Empresas

EssilorLuxottica Doesn't Disclose Financial Details

15 de out. de 2025, 16:50 UTC

Aquisições, Fusões, Aquisições de Empresas

EssilorLuxottica: RetinAI Partners With Pharmaceutical Companies, Research Organizations

15 de out. de 2025, 16:49 UTC

Aquisições, Fusões, Aquisições de Empresas

EssilorLuxottica: Deal Reinforces the Group's Med-Tech Journey

15 de out. de 2025, 16:48 UTC

Aquisições, Fusões, Aquisições de Empresas

EssilorLuxottica: Ikerian Specializes in Artificial Intelligence, Data Management in Eyecare

15 de out. de 2025, 16:48 UTC

Aquisições, Fusões, Aquisições de Empresas

EssilorLuxottica: Ikerian Is a Health Technology Company, Operating Under the RetinAI Brand

15 de out. de 2025, 16:47 UTC

Aquisições, Fusões, Aquisições de Empresas

EssilorLuxottica Buys Ikerian

15 de out. de 2025, 16:34 UTC

Conversa de Mercado

AMD Data Center Agreements Will Provide Big Revenue Growth -- Market Talk

Comparação entre Pares

Variação de preço

Kura Oncology Inc Previsão

Preço-alvo

By TipRanks

170.27% parte superior

Previsão para 12 meses

Média 26 USD  170.27%

Máximo 40 USD

Mínimo 11 USD

Com base em 13 analistas de Wall Street que oferecem metas de preço de 12 meses para Kura Oncology Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

13 ratings

11

Comprar

2

Manter

0

Vender

Pontuação Técnica

By Trading Central

5.575 / 6.6Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Strong Bullish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

323 / 371 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Baixa

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.
help-icon Live chat